Table 1.
Participant characteristics.
| Characteristica | PWH (n = 64) | Controls (n = 117) |
| HIV-related variables | ||
| Receiving antiretroviral therapy [n (%)] | 64 (100%) | – |
| Recent plasma viral load, copies HIV RNA/ml, median (IQR) | <50 (<50–<50) | – |
| Recent CD4+ T-cell count in cells/μl [median (IQR)] | 645 (473–958) | – |
| Nadir CD4+ T-cell count in cells/μl [median (IQR)] | 225 (95–485) | – |
| Sociodemographic and health variables | ||
| Age in years [median (IQR)] | 57 (42–65) | 47 (35–72) |
| Female sex at birth [n (%)] | 6 (9.4%) | 85 (73%) |
| White ethnicity [n (%)] | 46 (72%) | 64 (55%) |
| Number of chronic conditions [median (IQR)]b | 1 (1–3) | 0 (0–1) |
| Vaccine details | ||
| Initial regimen | ||
| mRNA only [n (%)] | 67 (81.2%) | 114 (97.4%) |
| ChAdOx1 only [n (%)] | 6 (9.4%) | 1 (0.9%) |
| ChAdOx1/mRNA [n (%)] | 6 (9.4%) | 2 (1.7%) |
| Third dose | ||
| BNT162b2 [n (%)] | 20 (31.2%) | 45 (38.5%) |
| mRNA-1273 [n (%)] | 44 (68.8%) | 72 (61.5%) |
| Days between second and third doses [median (IQR)] | 191 (182–240) | 198 (171–218) |
| Specimen collection | ||
| 1 month after third dose [n (%)] | 63 (98%) | 116 (99%) |
| 3 months after third dose [n (%)] | 58 (91%) | 116 (99%) |
| 6 months after third dose [n (%)] | 55 (86%) | 110 (94%) |
| Post-third dose SARS-CoV-2 infections [n (%)] | 24 (37.5%) | 45 (38.5%) |
IQR, interquartile range.
a
Sociodemographic, health and vaccine data were collected by self-report and confirmed through medical records wherever available.
b
Chronic conditions were defined as hypertension, diabetes, asthma, obesity, chronic diseases of lung, liver, kidney, heart or blood, cancer, and immunosuppression because of chronic conditions or medication.